Introduction
============

Metoprolol is a cardioselective beta-blocker that is used mainly in the treatment of arterial hypertension ([@B16]), heart failure ([@B24]), and myocardial infarction ([@B8]). Intestinal absorption of metoprolol is rapid and almost complete; however, due to an extensive first pass metabolism ([@B29]), the bioavailability of metoprolol is only approximately 50%. The half-life is in the range of 3--4 h in young adults and between 7--9 h in elderly patients ([@B30]). Metoprolol is heavily biotransformed with less than 5% of an oral dose being excreted in non-metabolized form by the kidneys ([@B29]; [@B25]; [@B30]; [@B19]). Approximately 70% of orally administered metoprolol is metabolized by CYP2D6 ([@B18]). Major oxidative pathways are O-demethylation to O-demethylmetoprolol and its further oxidation to the corresponding metoprolol phenylacetate (65% of the oral dose recovered in urine); N-dealkylation to N-deisopropylmetoprolol (10%), which may be transaminated and the resulting aldehyde oxidized to the corresponding acid; and α-hydroxylation to α-OH-metoprolol (10%) ([@B7]) (**Figure [1A](#F1){ref-type="fig"}**).

![Metabolic pathways of metoprolol and influence of CYP induction on the clearance of metoprolol and midazolam *in vivo*. **(A)** α-Hydroxylation (I), O-demethylation (II), and N-dealkylation (III) represent the 3 principle pathways of metoprolol metabolism, **(B)** midazolam clearance before and after treatment with rifampicin (600 mg rifampicin per day for 7 days), **(C)** metoprolol clearance before and after treatment with rifampicin (600 mg rifampicin per day for 7 days), and **(D)** α-OH-metoprolol exposure before and after treatment with rifampicin (600 mg rifampicin per day for 7 days). MDZ: midazolam, MTP: metoprolol.](fphar-09-00774-g001){#F1}

Whereas the carboxylic acid metabolites have no pharmacological activity, the α-OH-metabolite and O-demethylmetoprolol are active, but only contribute approximately 10% of the total beta-blocking activity of metoprolol ([@B28]). Importantly, in contrast to the formation of the carboxylic acid metabolites, the α-hydroxylation of metoprolol only involves one enzymatic step, which is considered to be mediated exclusively by CYP2D6 ([@B25]; [@B26]). Furthermore, the metabolism of metoprolol is stereoselective; in extensive CYP2D6 metabolizers (CYP2D6 EM), R-metoprolol has a 40% higher clearance than S-metoprolol ([@B6]).

Due to the exclusive nature by which CYP2D6 is responsible for α-hydroxylation of metoprolol, this step in the metabolic pathway of metoprolol has previously been used for the assessment of CYP2D6 activity *in vivo* ([@B32]; [@B31]; [@B12]; [@B10]; [@B9]) and *in vitro* ([@B5]). We have recently published a clinical study in healthy volunteers investigating the effect of CYP inhibitors and inducers on the Basel phenotyping cocktail, which contains six low-dosed commercially available drugs (caffeine, efavirenz, losartan, omeprazole, metoprolol, and midazolam) ([@B9]). After CYP induction with rifampicin, we not only observed a change in the phenotyping metric for CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4, but, albeit small, also for CYP2D6. CYP2D6 activity was evaluated through use of the metabolic ratio of metoprolol and its α-OH-metabolite, as well as the corresponding AUC~0--24~ ~h~ ratio. As CYP2D6 is considered to be non-inducible ([@B11]; [@B27]; [@B23]; [@B33]; [@B14]; [@B13]), this result was surprising and difficult to interpret.

Since it has been shown in a clinical study that the metabolism of metoprolol cannot be completely inhibited by quinidine ([@B18]), an efficient and specific CYP2D6 inhibitor ([@B17]; [@B1]), it is likely that apart from CYP2D6, other CYP isoforms are involved in the oxidative degradation of metoprolol, possibly also in its α-hydroxylation. Taking into account the results of our *in vivo* study ([@B9]), we predicted that these additional CYPs had to be inducible by rifampicin. In order to solve these questions, we decided to investigate metoprolol metabolism *in vitro* using two different hepatocyte systems as well as human liver microsomes and supersomes. The data obtained by our *in vitro* investigations confirmed that CYPs other than CYP2D6 are involved in metoprolol metabolism, explaining the decrease in the metoprolol/α-OH-metoprolol ratio after treatment with rifampicin observed *in vivo*.

Materials and Methods {#s1}
=====================

Chemicals and Reagents
----------------------

Metoprolol, α-OH-metoprolol, O-demethylmetoprolol, metoprolol phenylacetate, and metoprolol-d7 were purchased from TRC (Toronto, Canada). 1′-OH-midazolam and midazolam-d6 were acquired from Lipomed (Arlesheim, Switzerland), while rifampicin, ketoconazole, quinidine, and β-glucuronidase (type HP-2 from *Helix pomatia*) were obtained from Sigma-Aldrich (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). Midazolam was provided by Roche (Hoffmann-La Roche, Basel, Switzerland). Formic acid, HPLC grade methanol, and HPLC grade water were purchased from Merck (Darmstadt, Germany). The media used were purchased from GIBCO (Lucerne, Switzerland).

Stock solutions, calibration spiking solutions, and quality controls were prepared in DMSO. Calibration standards and quality controls were prepared by enriching the respective medium with the corresponding spiking solutions. Internal standard solutions containing the deuterated cocktail probe drugs were prepared in methanol.

Human Liver Microsomes and Cell Culture
---------------------------------------

Pooled human liver microsomes (HLM; Lot \#38289), and recombinant human CYP3A4 supersomes (rhCYP3A4 + P450 reductase + cytochrome b~5~, Lot \#4070007), and NADPH regenerating solutions A and B (*A*, containing NADP^+^, glucose-6-phosphate, and MgCl~2~; *B*, containing glucose-6-phosphate dehydrogenase) were purchased from Corning Life science (Woburn, MA, United States). Microsomes and supersomes were stored at −80°C until used.

HepaRG cells were purchased from Biopredic International (Rennes, France) as undifferentiated cryopreserved cells with the associated medium. Freshly split HepaRG cells were seeded at 9000 cells/well in 96-well plates (or 0.05 × 10^6^ cells/well in 24-well plates) and treated over the course of the next 4 weeks as previously described ([@B2]).

Primary cryopreserved human hepatocytes (Life Technologies, Lot \#Hu8119 and Lot \#Hu8124) were plated at 0.05 × 10^6^ cells/well in collagen type-1 precoated 96-well plates (or 0.25 × 10^6^ cells/well in 24-well plates) in William's E medium supplemented with 10% FCS (v/v), 1% L-glutamine 200 mM (v/v), 1% Pen Strep (v/v), 0.1% dexamethasone 100 μM (v/v), and 0.1% insulin 100 μM (v/v), and then incubated at 37°C in the presence of 5% CO~2~ and 95% humid air.

*In Vivo* Assessment of CYP Induction
-------------------------------------

The *in vivo* characterization of the Basel phenotyping cocktail has been described in detail in prior publications ([@B10]; [@B9]). The data presented here origin from one of these studies published previously ([@B9]). The study had been approved by the local ethics committee (Ethikkommission Basel) and the national regulatory authorities (Swiss Agency for Therapeutic Products, Swissmedic) and has been conducted in accordance with the ethical standards of the Declaration of Helsinki. It was a single-center, randomized, two-way crossover study ^[1](#fn01){ref-type="fn"}^ (ID: NCT01386593) that was conducted at the Phase I Research Unit, University Hospital Basel, Switzerland. In this study, CYP induction had been achieved by treating 15 healthy volunteers with 600 mg rifampicin per day for 7 days. Subjects ingested 12.5 mg metoprolol and 2 mg midazolam (and other CYP substrates) before and after CYP induction by rifampicin. Plasma samples were obtained and analyzed as described previously ([@B9]). We determined the AUC using the trapezoidal rule and apparent clearance (Cl/F) by dividing the oral dose administered for both metoprolol and midazolam with the respective AUCs. We used the ratio between the induced and the basal state of the Cl/F of midazolam as a marker of CYP3A4 induction.

Quantification of Gene Expression
---------------------------------

HepaRG cells and primary cryopreserved human hepatocytes were seeded in 24-well plates and treated for 48 h with rifampicin 20 μM. A total of 350 μL of RLT buffer (Qiagen, Hombrechtikon, Switzerland) was used to lyse the respective liver cell models, after which the lysate was transferred to Qiashredder columns and centrifuged for 2 min at 13,000 rpm. From the eluate, total RNA was extracted and purified according to the manufacturer's instructions (Qiagen, RNeasy mini extraction kit). The concentration of the extracted RNA was measured spectrophotometrically at 260 nm on a NanoDrop 2000 (Thermo Fisher Scientific, Wohlen, Switzerland). cDNA was reverse transcribed from the isolated RNA using the Qiagen omniscript system. For quantitative rt-PCR, 10 ng cDNA was used. Forward and reverse primers for all CYPs tested, and endogenous references, Hypoxanthine phosphoribosyltransferase 1 (HPRT1) and GAPDH, were purchased from Microsynth (Balgach, Switzerland; listed in **Table [1](#T1){ref-type="table"}**). rt-PCR was performed using SYBR green (Roche Diagnostics, Rotkreuz, Switzerland) on an ABI PRISM 7700 sequence detector (PE Biosystems, Rotkreuz, Switzerland). Quantification of mRNA expression levels was performed using the comparative-threshold cycle method ([@B22]).

###### 

Gene-specific primers for rt-PCR.

  Target Gene   Organism   Primer Sequence (5′ → 3′)   Length (bp)             
  ------------- ---------- --------------------------- ----------------------- ----
  CYP2D6        human      Fw                          TGTGCCCATCACCCAGAT      18
                           Rev                         AAGGTGGAGACGGAGAAGC     19
  CYP3A4        human      Fw                          TACACAAAAGCACCGAGTGG    20
                           Rev                         TGCAGTTTCTGCTGGACATC    20
  HPRT1         human      Fw                          GGTCCTTTTCACCAGCAAGCT   21
                           Rev                         TGACACTGGCAAAACAATGCA   21
  GAPDH         human      Fw                          AGCCACATCGCTCAGACAC     19
                           Rev                         GCCCAATACGACCAAATCC     19

Functional Assessment of CYP Induction
--------------------------------------

HepaRG cells and primary cryopreserved human hepatocytes were cultured in a 5% CO~2~ and 95% air-humidified atmosphere at 37°C. Induction treatment (rifampicin 20 μM) lasted for 48 h, with the medium being changed every 24 h. After medium change at 24 h, rifampicin (20 μM) was added again to the medium. Rifampicin stock solution was prepared in DMSO and further diluted in the appropriate culture medium, to achieve a final DMSO concentration of 0.1% (v/v). Experimental control culture wells were treated with solvent \[DMSO, 0.1% (v/v)\] alone. Following treatment with rifampicin, CYP activity was assessed by the addition of fresh medium containing the probe drugs (metoprolol 25 μM or midazolam 5 μM). Probe drugs were dissolved and serially diluted to the required concentrations with DMSO. The final concentration of DMSO during the incubation was 0.2% (v/v). At selected time points (0, 15, 30, 45, 60, 90, 105, and 120 min), the incubation was stopped by the addition of a threefold volume of ice-cold methanol containing the respective internal standards. The bottoms of the wells were scraped using a pipette tip, after which the contents were transferred to an autosampler vial. After vigorous shaking (10 min) and centrifugation (3220 × *g*; 30 min; 10°C), the supernatants were stored at −20°C until analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

To determine the total amount of 1′-OH-midazolam formed, the entire content of the autosampler vials was evaporated using a minivap microplate evaporator (Porvair Sciences Ltd., King's Lynn, Norfolk, United Kingdom). The analytes were then re-suspended in 45 μl of the respective culture medium, to which 5 μl (500 units) of β-glucuronidase was added. Following a 12-h incubation at 37°C, the reaction was terminated by the addition of methanol, after which the samples were treated in the same manner as above.

Metabolism of Metoprolol and Midazolam by Human Liver Microsomes and by rhCYP3A4 Supersomes
-------------------------------------------------------------------------------------------

The reaction mixture (final volume of 500 μL) contained the probe drugs (metoprolol 25 μM or midazolam 5 μM), incubation buffer (0.1 M potassium phosphate buffered saline, pH 7.4), human liver microsomes (175 pmol cytochrome P450/500 μL) or rhCYP3A4 (10 pmol CYP3A4/500 μL) and a NADPH-generating system. For inhibition studies, the reaction mixture was pre-incubated with the specific inhibitors (concentrations indicated in the figures) for 10 min prior to the addition of test compounds and NADPH. The suspensions were incubated at 37°C in a thermomixer (compact 5350, Eppendorf, Hamburg, Germany). Following the incubation in the absence (control) or presence of inhibitors, the reactions were terminated at selected time-points by transferring 50 μL of the incubation mixture into a matrix autosampler vial, to which a threefold volume of ice-cold methanol (containing the internal standards) was added. After vigorous shaking (10 min) and centrifugation (3220 × *g*; 30 min; 10°C) the samples were stored at −20°C until analysis by LC-MS/MS. The formation rate (pmol/min/pmol P450) in the absence and the presence of the inhibitors was calculated from the linear parts of the concentration-time curves and expressed as an absolute value or as a percentage relative to the control values.

Quantification of Probe Substrate Metabolites
---------------------------------------------

A previously developed LC-MS/MS method ([@B10]) was used to quantify the phase I metabolites of metoprolol and midazolam. Chromatographic separation was performed on a Shimadzu HPLC system (Shimadzu AG, Reinach, Switzerland), coupled to a triple quadrupole tandem mass spectrometer (API4000 or API5500, AB/MDS Sciex, Concord, Canada), operating in positive electrospray ionization mode. The total run time was 2.9 min. Inter-assay accuracy (determined as the % bias) ranged from −8.6 to 8.9 and inter-assay precision (determined as the CV%) was lower than 8.3 for all analytes. The lower limit of quantification (LLOQ) utilizing the API 4000 was 0.25 ng/mL for α-OH-metoprolol and 1′-OH-midazolam, whereas on the API5500 the LLOQ for α-OH-metoprolol, O-demethylmetoprolol, and metoprolol phenylacetate (see **Figure [1A](#F1){ref-type="fig"}** for chemical structures) was 0.025 ng/mL.

Data Analysis
-------------

The CYP activities were determined as the respective metabolite formation rates corresponding to the slope in the metabolite concentration versus time graphs. Metabolite concentrations were quantified using standard curves of pure compounds as previously described ([@B10]).

For induction experiments, metabolite formation rates were determined as described above, and the fold change versus the basal conditions was calculated as the ratio of the metabolite formation rate in wells exposed to an inducer versus formation rates in control wells.

Experiments were carried out 5 times unless stated otherwise. Means were compared with the two-tailed Student's *t*-test using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, United States). Data are presented as mean ± SD unless stated otherwise. Induction levels above twofold with statistically significant differences (*p* \< 0.05) were considered relevant. Areas under the curve (AUC), from times 0--24 h after dosing (AUC~0--24~ ~h~), were estimated with non-compartmental methods using Phoenix WinNonlin software (Certara, Princeton, NJ, United States).

Results
=======

*In Vivo* Clearance of Metoprolol Before and After Treatment With Rifampicin
----------------------------------------------------------------------------

We performed a clinical study using 15 healthy volunteers, where we investigated the effect of pre-treatment with rifampicin on the Basel phenotyping cocktail, which contains caffeine, efavirenz, losartan, omeprazole, metoprolol, and midazolam as probe drugs. We have reported the changes in the metabolic ratios induced by rifampicin of the six substrates included in a previous publication ([@B9]). As expected, we observed an increase in the clearance of midazolam (**Figure [1B](#F1){ref-type="fig"}**) in all subjects tested, which is a marker of CYP3A4 activity ([@B21]). Surprisingly, we also observed a 25% increase in the clearance of metoprolol in subjects treated with rifampicin compared to the basal conditions (**Figure [1C](#F1){ref-type="fig"}**). An increase by 9% (statistically not significant) was also observed in the formation of α-OH-metoprolol after treatment with rifampicin (**Figure [1D](#F1){ref-type="fig"}**).

The findings regarding metoprolol suggested either an induction of CYP2D6 by rifampicin and/or metabolism of metoprolol by CYPs other than 2D6, which are inducible by rifampicin. To study the induction of the metabolism of metoprolol by rifampicin in more detail, we performed *in vitro* investigations in HepaRG cells and primary human hepatocytes as well as in human liver microsomes and supersomes.

mRNA Expression of CYP2D6 and CYP3A4, and Midazolam and Metoprolol Metabolism Before and After Rifampicin in HepaRG Cells
-------------------------------------------------------------------------------------------------------------------------

First, we reproduced the *in vivo* findings in HepaRG cells, which contain inducible CYPs ([@B4]). As shown in **Figure [2](#F2){ref-type="fig"}**, we investigated the effect of CYP induction by rifampicin on mRNA expression and activity of CYP2D6 and CYP3A4.

![Effect of rifampicin on mRNA expression and metabolism of midazolam and metoprolol in HepaRG cells. HepaRG cells were exposed to 20 μM rifampicin for 48 h. **(A)** mRNA expression of CYP2D6 and CYP3A4 before and after treatment with rifampicin, **(B)** formation of 1′-OH-midazolam before and after treatment with rifampicin, and **(C)** formation of α-OH-metoprolol before and after treatment with rifampicin. Data are presented as mean ± SD. MDZ: midazolam, MTP: metoprolol.](fphar-09-00774-g002){#F2}

In HepaRG cells, mRNA of CYP3A4 (determined as a positive control) increased approximately 30-fold after treatment with rifampicin (20 μM for 48 h) compared to basal conditions (**Figure [3A](#F3){ref-type="fig"}**). In contrast, mRNA of CYP2D6 was not induced by pre-treatment with rifampicin.

![Effect of rifampicin on mRNA expression and metabolism of midazolam and metoprolol in primary human hepatocytes. Primary human hepatocytes were exposed to 20 μM rifampicin for 48 h. **(A)** mRNA expression of CYP2D6 and CYP3A4 before and after treatment with rifampicin, **(B)** formation of 1′-OH-midazolam before and after treatment with rifampicin, **(C)** formation of α-OH-metoprolol before and after treatment with rifampicin, **(D)** formation of 1′-OH-midazolam, α-OH-metoprolol, O-demethyl-metoprolol, and metoprolol phenylacetate before and after treatment with rifampicin. Experiments for **(A--C)** were carried out with lot \#Hu8119 and experiments for **(D)** with lot \#Hu8124. Data are presented as mean ± SD. MDZ: midazolam, MTP: metoprolol.](fphar-09-00774-g003){#F3}

In agreement with the mRNA data, pre-treatment with rifampicin was associated with a significant increase in the formation of 1′-OH-midazolam (**Figure [2B](#F2){ref-type="fig"}**), reflecting induction of CYP3A4 by rifampicin. In contrast to the results obtained for CYP2D6 mRNA, pre-treatment with rifampicin was also associated with a significant increase in α-OH-metoprolol formation (**Figure [2C](#F2){ref-type="fig"}**). This result suggested that CYPs other than CYP2D6 contribute to α-hydroxylation of metoprolol and that the contribution becomes larger after CYP induction.

mRNA Expression of CYP2D6 and CYP3A4, and Midazolam and Metoprolol Metabolism Before and After Rifampicin in 2D Primary Hepatocytes
-----------------------------------------------------------------------------------------------------------------------------------

In order to confirm the results obtained in HepaRG cells, we performed similar experiments in primary human hepatocytes (Lot \#Hu8119). Identical to our findings in HepaRG cells, pre-treatment with rifampicin was associated with a 16-fold increase in CYP3A4 mRNA expression, whereas no increase in mRNA expression levels could be observed for CYP2D6 (**Figure [3A](#F3){ref-type="fig"}**).

Pre-treatment with rifampicin led to a fivefold increase in production of 1′-OH-midazolam (**Figure [3B](#F3){ref-type="fig"}**). Similar to the findings in HepaRG cells, rifampicin increased α-hydroxylation of metoprolol also in primary human hepatocytes (**Figure [3C](#F3){ref-type="fig"}**), but to a lesser extent than in HepaRG cells. These findings confirmed the results obtained with HepaRG cells and excluded at the same time an artifact due to modified regulation of CYP expression in the HepaRG hepatoma cell line.

Using a different batch of primary cryopreserved human hepatocytes (Lot \#Hu8124) we could confirm the results regarding the formation of 1′-OH-midazolam and α-hydroxylation of metoprolol (**Figure [3D](#F3){ref-type="fig"}**). Furthermore, we also investigated the formation of O-demethyl-metoprolol and its oxidation to metoprolol phenylacetate. Similar to the increase in the formation of α-OH-metoprolol, pre-treatment with rifampicin was also associated with an increase in O-demethylation of metoprolol (factor 1.4) and in the conversion of O-demethyl-metoprolol to the corresponding phenylacetate metabolite (factor 1.6).

These experiments not only confirmed the previous results in HepaRG cells and primary human hepatocytes, but also showed that CYPs other than CYP2D6 contribute to O-demethylation of metoprolol, the most important metabolic pathway of this drug ([@B7]; [@B29]).

CYPs Involved in the Metabolism of Metoprolol in Human Liver Microsomes
-----------------------------------------------------------------------

Next, we investigated the metabolic pathways of metoprolol in human liver microsomes in the presence of different inhibitors. In the presence of quinidine, a specific and strong inhibitor of CYP2D6 ([@B17]; [@B1]), α-hydroxylation, O-demethylation, and N-dealkylation of metoprolol was not blocked completely (**Figures [4A--C](#F4){ref-type="fig"}** and **Table [2](#T2){ref-type="table"}**), again suggesting the involvement of CYPs other than CYP2D6 in metoprolol metabolism. In comparison, the formation of the phenylacetate metabolite from O-demethylated metoprolol had a very low activity and was blocked completely by quinidine (**Figure [4D](#F4){ref-type="fig"}**). These findings were in agreement with the *in vitro* study of [@B26] and the *in vivo* studies of [@B20] and of [@B25], showing residual metabolism of metoprolol in the absence of functional CYP2D6.

![Effect of quinidine on the metabolism of metoprolol by human liver microsomes. The quinidine concentration was 1 μM. **(A)** formation of α-OH-metoprolol, **(B)** formation of O-demethyl-metoprolol, **(C)** formation of metoprolol phenylacetate, and **(D)** formation of N-deisopropyl-metoprolol. Data are analyzed in **Table [2](#T2){ref-type="table"}**. Data are presented as mean ± SD. MTP: metoprolol.](fphar-09-00774-g004){#F4}

###### 

Metoprolol metabolism by human liver microsomes in the absence (w/o) and presence of inhibitors.

  Metabolite formed                            w/o inhibitor fmol/min/pmol CYP   with inhibitor fmol/min/pmol CYP   \% residual activity (quinidine) or % inhibition (ketoconazole, ticlopidine, sulfaphenazole, (+)-N-3-benzylnirvanol)
  -------------------------------------------- --------------------------------- ---------------------------------- ----------------------------------------------------------------------------------------------------------------------
  **Quinidine 1 μM (CYP2D6)**                                                                                       
  O-demethyl-MTP                               17.5 ± 0.3                        3.32 ± 0.40                        19.0 ± 2.1 (2.6)
  α-OH-MTP                                     4.11 ± 0.06                       0.16 ± 0.06                        4.0 ± 0.6 (0.70)
  MTP-phenylacetate                            0.91 ± 0.0.05                     0                                  0
  N-dealkyl-MTP                                2.91 ± 0.06                       0.22 ± 0.05                        7.6 ± 1.7 (2.1)
  **Ketoconazole 1 μM (CYP3A4)**                                                                                    
  O-demethyl-MTP                               26.6 ± 0.0.6                      22.0 ± 0.0.8                       17.5 ± 3.4 (4.3)
  α-OH-MTP                                     6.86 ± 0.0.23                     5.71 ± 0.29                        16.8 ± 2.4 (3.0)
  N-dealkyl-MTP                                4.86 ± 0.29                       4.38 ± 0.23                        9.9 ± 1.7 (2.1)
  **Ticlopidine 1 μM (CYP2B6)**                                                                                     
  O-demethyl-MTP                               30.3 ± 3.3                        24.2 ± 0.34                        20.2 ± 8.0 (9.9)
  α-OH-MTP                                     7.43 ± 1.14                       5.71 ± 0.0.29                      23.2 ± 11.1 (13.7)
  N-dealkyl-MTP                                4.97 ± 1.03                       3.74 ± 0.23                        24.8 ± 12.7 (15.8)
  **Sulfaphenazole 10 μM (CYP2C9)**                                                                                 
  O-demethyl-MTP                               27.7 ± 0.40                       20.3 ± 2.4                         26.5 ± 10.4 (13.2)
  α-OH-MTP                                     6.40 ± 0.23                       4.67 ± 0.57                        27.0 ± 9.8 (12.2)
  N-dealkyl-MTP                                4.51 ± 0.0.46                     3.83 ± 0.74                        15.2 ± 14.5 (18.0)
  **(+)-N-3-benzylnirvanol 10 μM (CYP2C19)**                                                                        
  O-demethyl-MTP                               25.8 ± 0.6                        25.0 ± 1.43                        3.1 ± 8.4 (10.4)
  α-OH-MTP                                     6.23 ± 0.23                       6.23 ± 0.0.34                      0
  N-dealkyl-MTP                                4.29 ± 0.17                       4.29 ± 0.23                        0

Metoprolol metabolites were determined by LC/MS as described in the Section "Materials and Methods." Activity is given as pmol/min/pmol CYP. Data are given as mean ± SD and 95%CI in parentheses for residual activity. CYP: cytochrome P450 enzyme, MTP: metoprolol.

Next, we investigated, which additional CYPs are involved in the metabolism of metoprolol. In the presence of ketoconazole, at the concentration used (1 μM) a specific inhibitor of CYP3A4 ([@B4]), all major metabolic pathways assessed (O-demethylation, α-hydroxylation, and N-dealkylation) were inhibited significantly by 9.9--17.5% (**Table [2](#T2){ref-type="table"}** and Supplementary Figure [1](#SM1){ref-type="supplementary-material"}). In comparison, the CYP2B6 inhibitor ticlopidine significantly reduced the activities of all metabolic pathways of metoprolol investigated by 20.2--24.8% (**Table [2](#T2){ref-type="table"}** and Supplementary Figure [2](#SM2){ref-type="supplementary-material"}). Similarly, the CYP2C9 inhibitor sulfaphenazole reduced the activities of all metabolic pathways by 15.2--27.0%, reaching statistical significance for O-demethylation and α-hydroxylation (**Table [2](#T2){ref-type="table"}**, Supplementary Figure [3](#SM3){ref-type="supplementary-material"}). In contrast, the CYP2C19 inhibitor (+)-N-3-benzylnirvanol did not significantly decrease the activity of metoprolol metabolism (**Table [2](#T2){ref-type="table"}**, Supplementary Figure [4](#SM4){ref-type="supplementary-material"}).

These results indicated that the major part of metoprolol is metabolized by CYP2D6, but that CYP3A4, CYP2B6 and CYP2C9 contribute significantly to the metabolism of metoprolol. Since CYP3A4, 2B6, and 2C9 are inducible by rifampicin ([@B4]), the results obtained in microsomes supported our *in vivo* findings as well as the results obtained in HepaRG cells and in primary human hepatocytes.

α-Hydroxylation of Metoprolol by rhCYP3A4 Supersomes
----------------------------------------------------

In order to demonstrate directly that CYP3A4 can α-hydroxylate metoprolol, we performed experiments using recombinant supersomes expressing CYP3A4 (rhCYP3A4). To ensure that these supersomes do not contain CYP2D6 activity, we exposed them to dextromethorphan, a typical CYP2D6 substrate ([@B12]). The conversion to dextrorphan was not quantifiable, excluding a significant CYP2D6 activity (data not shown).

As shown in **Figure [5A](#F5){ref-type="fig"}**, the formation of 1′-OH-midazolam from midazolam by CYP3A4 overexpressing supersomes was rapid, showing non-linearity after 4 min of incubation due to substrate depletion. Midazolam 1′-hydroxylation could almost completely be inhibited by 1 μM ketoconazole, at this concentration a specific CYP3A4 inhibitor ([@B4]). Crucially, metoprolol was also α-hydroxylated by CYP3A4 supersomes, but at a much slower rate compared to midazolam.

![α-Hydroxylation of metoprolol and 1′-hydroxylation of midazolam by CYP3A4 overexpressing supersomes. **(A)** α-Hydroxylation of metoprolol and 1′-hydroxylation of midazolam. 1′-hydroxylation of midazolam was also determined in the presence of 0.5 μM ketoconazole (CYP3A4 inhibitor). **(B)** α-hydroxylation of metoprolol in the absence and in the presence of 1 μM quinidine (CYP2D6 inhibitor) or 0.5 μM ketoconazole (CYP3A4 inhibitor). Data are presented as mean ± SD. MDZ: midazolam, MTP: metoprolol.](fphar-09-00774-g005){#F5}

As shown in **Figure [5B](#F5){ref-type="fig"}**, α-hydroxylation of metoprolol could be inhibited by 1 μM ketoconazole, but not by quinidine, which is a specific CYP2D6 inhibitor ([@B17]; [@B1]). This proved directly that α-hydroxylation of metoprolol could not only be catalyzed by CYP2D6 but to a small extent also by CYP3A4.

Discussion
==========

Starting from our *in vivo* observation that treatment with rifampicin was associated with an increase in the clearance of metoprolol, we investigated the metabolic pathways of metoprolol in different metabolic systems *in vitro*. In HepaRG cells and primary human hepatocytes, we could show that not only CYP2D6 contributes to metoprolol metabolism, but also other CYP isoforms which are inducible by rifampicin. Subsequently, we could demonstrate in human liver microsomes that CYP2D6 is the dominant CYP for metoprolol metabolism, but that CYP3A4, 2B6, and 2C9 are also involved in the three major pathways of metoprolol degradation. Finally, we could confirm these findings directly using CYP3A4 overexpressing supersomes, which had no CYP2D6 activity but could perform metoprolol α-hydroxylation.

The *in vivo* investigations showed a 25% increase in metoprolol clearance, but only a small (9%) increase in the AUC of α-OH-metoprolol after CYP induction with rifampicin. This is consistent with previous findings, which also showed a decrease in the AUC of metoprolol after CYP induction ([@B15]; [@B3]; [@B9]). The *in vivo* results could be reproduced in two hepatocyte models, HepaRG cells (a hepatoma cell line) and primary human hepatocytes. The results obtained in these cell systems showed that both α-hydroxylation and O-demethylation of metoprolol were induced by pre-treatment with rifampicin, while CYP2D6 mRNA expression was not affected.

The lacking increase in CYP2D6 mRNA expression by rifampicin observed in the current study agrees with other studies in primary human hepatocytes ([@B27]; [@B13]; [@B4]). In enterocytes of human subjects treated with 600 mg rifampicin for 10 days, the CYP2D6 protein expression increased by a factor of 1.6 without reaching statistical significance ([@B14]). Post-transcriptional mechanisms increasing CYP2D6 activity cannot be excluded based on the current study, but are an unlikely cause for our observations. In support of this interpretation, sparteine metabolic clearance, an *in vivo* marker of CYP2D6 activity ([@B25]), increased by a factor of 1.3 in subjects treated with rifampicin without reaching statistical significance ([@B11]). Similarly, in primary human hepatocytes, the activity of dextromethorphan O-demethylation increased by a factor of 1.3 by treatment with rifampicin without reaching statistical significance ([@B23]). In the same publication, phenobarbital had an almost identical effect on dextromethorphan O-demethylation as rifampicin ([@B23]). Similarly, hypericum extract did not significantly affect the metabolic ratio of dextrorphan/dextromethorphan, indicating that CYP2D6 is not induced by this treatment ([@B33]).

The data of the current and the previous studies mentioned above show that CYP2D6 activity is not increased by the classical inducers of the CYP2B, 2C, and 3A families. The observed increase in the metoprolol metabolic pathways after treatment with rifampicin suggested therefore the contribution of CYPs other than CYP2D6 to metoprolol metabolism. In order to challenge this hypothesis further, we investigated the metabolism of metoprolol in human liver microsomes and in CYP3A4 overexpressing supersomes. The data obtained in microsomes confirmed the contribution of CYP3A4, 2B6, and 2C9 (but not 2C19) to all 3 major metabolic pathways of metoprolol. Finally, using CYP3A4 overexpressing supersomes, we could demonstrate directly that metoprolol can be α-hydroxylated by CYP3A4.

In human liver microsomes, inhibition of CYP2D6 activity with quinidine revealed residual activities amassing to 4% for α-hydroxylation, 8% for N-dealkylation, and 19% for O-demethylation of metoprolol. Considering these values, it has to be taken into account, that the microsomes used in the current study were obtained from donors without CYP induction. Based on the data of the current and previous studies ([@B15]; [@B3]; [@B9]), it can be assumed that the contribution of CYP3A4, CYP2C9, and CYP2B6 becomes larger after CYP induction. In primary human hepatocytes treated with rifampicin, the production of the metoprolol phenylacetate metabolite (the end product of the O-demethylation pathway) and of α-OH-metoprolol increased by 57 and 75%, respectively (**Figure [3D](#F3){ref-type="fig"}**), suggesting that the contribution of CYPs other than CYP2D6 for metoprolol metabolism can be substantial after CYP induction. The *in vivo* study revealed a 25% decrease in the metoprolol AUC, which is less than expected from the *in vitro* experiments. This difference may be due to a more efficient CYP induction under *in vitro* conditions, depending on the availability of rifampicin. In comparison, the increase in the AUC of α-OH-metoprolol in the *in vivo* study was only 9%, which can be explained by the only small contribution of CYPs other than CYP2D6 to this metabolic step (**Figure [4A](#F4){ref-type="fig"}**).

The question now arises whether metoprolol can be recommended as a substrate for CYP2D6 phenotyping, taking into account the contribution of CYPs other than CYP2D6 to metoprolol metabolism. The problem could be that CYP2D6 poor metabolizers might not be recognized due to the contribution of CYPs other than CYP2D6, which are not affected by this polymorphism. In the study of [@B25], there was a clear separation in renal excretion of α-OH-metoprolol into debrisoquine EM and PM. Also in the studies of [@B32] and of [@B9], CYP2D6 efficient and poor metabolizers could clearly be distinguished using α-OH-metoprolol plasma concentrations or the metoprolol/α-OH-metoprolol ratio. A further potential problem could be the distinction between CYP2D6 efficient and poor metabolizers in patients with CYP induction. However, also in this situation, it was possible to correctly classify patients using their respective α-OH-metoprolol plasma concentrations or the metoprolol/α-OH-metoprolol ratio ([@B9]). The findings of the current and of our previous study ([@B9]) suggest that the plasma α-OH-metoprolol concentration is a better marker of CYP2D6 activity than the ratio of the metoprolol/α-OH-metoprolol concentrations, since the contribution of CYPs different from CYP2D6 is smaller for metoprolol α-hydroxylation than for metoprolol O-demethylation or N-dealkylation. However, as shown in the study of [@B9], a correct classification of CYP2D6 poor metabolizers using the metoprolol/α-OH-metoprolol ratio was possible under basal conditions and also after CYP-induction.

Conclusion
==========

CYP3A4, 2B6, and 2C9 contribute to metoprolol metabolism, including α-hydroxylation. This contribution explains a more pronounced decrease in the metoprolol and a more pronounced increase in the α-OH-metoprolol plasma concentration after CYP induction by rifampicin compared to basal conditions. However, the contribution of CYPs other than CYP2D6 is low and does not impair the usability of the metoprolol/α-OH-metoprolol metabolic ratio for CYP2D6 phenotyping, even in patients with CYP induction by rifampicin.
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